Why the study?
Does interhospital transfer for primary percutaneous coronary intervention reduce adverse cardiovascular events compared to immediate thrombolysis in STEMI patients presenting to hospitals without catheterization laboratories?
Does interhospital transfer for primary percutaneous coronary intervention reduce adverse cardiovascular events compared to immediate thrombolysis in STEMI patients presenting to hospitals without catheterization laboratories?
The early clinical benefit of interhospital transfer for primary PCI over immediate thrombolysis in STEMI patients is sustained at 5 years, driven almost exclusively by differences in event rates during the first month.
Answers are grounded in this paper and cite their sources.
Supports transfer for p-PCI over thrombolysis in STEMI without on-site labs; extends early benefit to sustained 5-year outcomes.
AIM: Randomized trials in ST-elevation myocardial infarction (STEMI) showed improved early outcomes after primary percutaneous coronary intervention (p-PCI) compared with thrombolysis (TL). It is less known whether the early benefit is sustained during the long-term follow-up. METHODS AND RESULTS: The PRAGUE-2 trial enrolled 850 STEMI patients presenting to community hospitals without cath-labs within 12 h of symptom onset. Patients were randomized into the groups 'TL in community hospital' (n = 421) and 'interhospital transfer for p-PCI' (n = 429). Follow-up data were available in 416 (98.8%) patients in the TL group and 428 (99.8%) in the p-PCI group. At 5 year follow-up, the cumulative incidence of composite endpoint (death from any cause or recurrent infarction or stroke or revascularization) was 53% in TL patients compared with 40% in p-PCI patients (HR 1.8; 95% CI 1.38-2.33; P < 0.001). The respective cumulative incidence of death from any cause was 23 and 19% (HR 1.34; 95% CI 0.99-1.82; P = 0.06), recurrent infarction 19 vs. 12% (HR 1.72; 95% CI 1.15-2.58; P = 0.009), stroke 8 vs. 8% (HR 1.65; 95% CI 0.84-2.23; P = 0.18), revascularization 51 vs. 34% (HR 1.81; 95% CI 1.21-2.35; P < 0.001). CONCLUSION: The early benefit from the p-PCI strategy (over TL) is sustained during the 5 years' follow-up. It can be almost exclusively derived from differences in event rate during the first month.
No takes yet. Share an insight, caveat, or question.
Widimský et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: